Antitrust
Practice AreasJustice
Delivered
An antitrust firm at the forefront, prosecuting some of the most noteworthy antitrust class actions
Berman Tabacco has provided FPPA with superior monitoring and evaluation services for years, offering careful and astute legal advice. In litigation, they are aggressive yet professional. FPPA always feels well represented with Berman Tabacco.
Berman Tabacco’s Antitrust Practice Group has a national reputation for prosecuting antitrust class action lawsuits involving price-fixing, market allocation agreements, patent misuse, monopolization and group boycotts among other types of anticompetitive conduct. For decades, Berman Tabacco has been at the forefront of some of the largest antitrust cases and has achieved substantial class action settlements and changed business practices of defendant companies. The firm has successfully prosecuted numerous landmark antitrust lawsuits, including the first lawsuit to successfully challenge a brand-name drug manufacturer’s “pay-for-delay” efforts to block entry of a cheaper generic drug.
Berman Tabacco is consistently recognized as one of the top antitrust class action law firms by prominent legal publications including Benchmark Litigation, The Legal 500, U.S. News & World Report—Best Lawyers®, Best Law Firms and the Daily Journal, among others.
Working tirelessly on behalf of plaintiffs across a variety of industries—from purchasers of prescription drugs, automobiles, diamonds and batteries, to large institutional investors of derivatives and other financial instruments—Berman Tabacco’s antitrust lawyers have recovered over $1 billion for aggrieved victims of anticompetitive practices. Our strong track record can be attributed to our decades of experience and core philosophy of careful case selection.
In addition to pursuing litigation against price-fixing cartels and monopolists, Berman Tabacco’s Antitrust Practice Group also represents large institutional investors in lawsuits alleging manipulation of financial benchmarks, such as the Euribor and Euroyen cases. These actions allege violations of not only antitrust laws, but also of the Commodity Exchange Act and other laws.
Notable achievements include:
- Sullivan v. DB Investments, Inc., No. 04-02819 (D.N.J.) ($295 million settlement)
- In re Automobile Antitrust Cases I and II, JCCP Nos. 4298 and 4303 (Cal. Super. Ct. San Francisco) ($137 million settlement)
- In re Lithium Ion Batteries Antitrust Litigation, No. 13-MD-2420-YGR (N.D. Cal.) ($139.3 million settlement)
- In re Cardizem CD Antitrust Litigation, No. 99-01278 (E.D. Mich.) ($80 million settlement in pioneer pay-for-delay case)
- Sullivan v. Barclays PLC, et al.v, No. 13-cv-2811 (S.D.N.Y.) (Euribor) (partial settlements total $546.5 million)
- In re GSE Bonds Antitrust Litigation, No. 1:19-CV-01704-JSR (S.D.N.Y.) ($386.5 million settlement)
- Laydon v. Mizuho Bank, Ltd., No. 1:12-cv-03419 (GBD) (S.D.N.Y.), and Sonterra Capital Master Fund, Ltd. v. UBS AG, No. 1:15-cv-05844 (GBD) (S.D.N.Y). (Euroyen) (partial settlements total $329.5 million)
Berman Tabacco’s Antitrust Practice Group has a national reputation for prosecuting antitrust class action lawsuits involving price-fixing, market allocation agreements, patent misuse, monopolization and group boycotts among other types of anticompetitive conduct. For decades, Berman Tabacco has been at the forefront of some of the largest antitrust cases and has achieved substantial class action settlements and changed business practices of defendant companies. The firm has successfully prosecuted numerous landmark antitrust lawsuits, including the first lawsuit to successfully challenge a brand-name drug manufacturer’s “pay-for-delay” efforts to block entry of a cheaper generic drug.
Berman Tabacco is consistently recognized as one of the top antitrust class action law firms by prominent legal publications including Benchmark Litigation, The Legal 500, U.S. News & World Report—Best Lawyers®, Best Law Firms and the Daily Journal, among others.
Working tirelessly on behalf of plaintiffs across a variety of industries—from purchasers of prescription drugs, automobiles, diamonds and batteries, to large institutional investors of derivatives and other financial instruments—Berman Tabacco’s antitrust lawyers have recovered over $1 billion for aggrieved victims of anticompetitive practices. Our strong track record can be attributed to our decades of experience and core philosophy of careful case selection.
In addition to pursuing litigation against price-fixing cartels and monopolists, Berman Tabacco’s Antitrust Practice Group also represents large institutional investors in lawsuits alleging manipulation of financial benchmarks, such as the Euribor and Euroyen cases. These actions allege violations of not only antitrust laws, but also of the Commodity Exchange Act and other laws.
Notable achievements include:
- Sullivan v. DB Investments, Inc., No. 04-02819 (D.N.J.) ($295 million settlement)
- In re Automobile Antitrust Cases I and II, JCCP Nos. 4298 and 4303 (Cal. Super. Ct. San Francisco) ($137 million settlement)
- In re Lithium Ion Batteries Antitrust Litigation, No. 13-MD-2420-YGR (N.D. Cal.) ($139.3 million settlement)
- In re Cardizem CD Antitrust Litigation, No. 99-01278 (E.D. Mich.) ($80 million settlement in pioneer pay-for-delay case)
- Sullivan v. Barclays PLC, et al.v, No. 13-cv-2811 (S.D.N.Y.) (Euribor) (partial settlements total $546.5 million)
- In re GSE Bonds Antitrust Litigation, No. 1:19-CV-01704-JSR (S.D.N.Y.) ($386.5 million settlement)
- Laydon v. Mizuho Bank, Ltd., No. 1:12-cv-03419 (GBD) (S.D.N.Y.), and Sonterra Capital Master Fund, Ltd. v. UBS AG, No. 1:15-cv-05844 (GBD) (S.D.N.Y). (Euroyen) (partial settlements total $329.5 million)